Genesystem Co., Ltd.
KKRX:3632503,985.00
KRW
-65.00
(-1.60%)
ISIN
KR7363250002
Return %
Stock
S&P 500
1Y
-34.78
14.39
3Y
-63.74
81.42
5Y
-65.65
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yu-Jin Seo
- Full Time Employees
- 52
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Daejeon South Korea
- IPO Date
- May 26, 2021
- Website
- genesystem.co.kr
- Similar Companies
- Business
- Genesystem Co., Ltd. is a South Korea-based in vitro molecular diagnostics company primarily engaged in the development, manufacture, and commercialization of rapid point-of-care testing (POCT) real-time polymerase chain reaction (PCR) platforms, microfluidic biochips, and diagnostic reagent kits. Founded in 2010 and headquartered in Daejeon, South Korea, the company serves clinical healthcare providers, veterinary clinics, research laboratories, and food safety institutions across domestic and international markets, including Asia-Pacific, Europe, the Middle East, and the Americas. Genesystem operates through integrated diagnostic product lines and services, which include: point-of-care molecular diagnostic instruments under the GENECHECKER brand, featuring the UF-100, UF-150, and UF-300 series ultra-fast real-time quantitative PCR analyzers; proprietary microfluidic lab-on-a-chip consumables, such as Rapi-Disk biochips, SMART CHEK microfluidic reaction plates, and specialized optical assay cartridges; human clinical diagnostic assay kits under the SMARTCHEK brand, spanning multiplex respiratory infection panels (including COVID-19, influenza A/B, and respiratory syncytial virus), tuberculosis, human papillomavirus (HPV), sexually transmitted infections, and vector-borne tropical diseases; companion animal and veterinary diagnostic kits designed for rapid on-site detection of canine and feline respiratory and enteric pathogens; food safety testing kits targeting common foodborne bacterial pathogens; and original equipment manufacturing (OEM) and custom assay development services for diagnostic biochip systems. In recent strategic and operational developments, Genesystem has expanded its international commercialization network by securing strategic distribution agreements in Southeast Asian and Middle Eastern markets, broadened its veterinary diagnostics business through partnerships with animal healthcare networks, introduced next-generation multi-channel real-time PCR diagnostic systems and expanded multiplex infectious disease test menus, and scaled automated cleanroom manufacturing facilities to increase commercial biochip production capacity.